Vivodyne to Transform Drug Discovery with $40 Million Funding Boost

Vivodyne, a company focused on shifting drug discovery from animal models to human tissue-based testing, has secured $40 million in Series A financing. Led by Khosla Ventures with participation from new and existing investors, this funding allows Vivodyne to open a state-of-the-art 23,000-square-foot robotic laboratory aimed at enhancing its capabilities to generate detailed human data. The initiative aligns with recent public and regulatory movements to diminish reliance on animal models, which fail nearly 95% of the time in predicting human outcomes. Vivodyne's technology utilizes robotics and AI to test thousands of lab-grown human tissues, offering pharmaceutical clients unprecedented insights before commencing costly clinical trials. This shift is poised to significantly improve success rates in human trials, transforming the landscape of drug development.